162 related articles for article (PubMed ID: 6743563)
21. Mixed myelodysplastic syndrome and myeloproliferative disorder with bone marrow and pulmonary fibrosis: the role of megakaryocytes.
Rosenstingl S; Brouland JP; Zini JM; Tobelem G; Dupuy E
Acta Haematol; 2003; 109(3):145-9. PubMed ID: 12714825
[TBL] [Abstract][Full Text] [Related]
22. A reversible defect of platelet PDGF content in myeloproliferative disorders.
Baglin TP; Price SM; Boughton BJ
Br J Haematol; 1988 Aug; 69(4):483-6. PubMed ID: 3408684
[TBL] [Abstract][Full Text] [Related]
23. Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders.
Cortellazzo S; Viero P; Buczko W; Barbui T; de Gaetano G
Scand J Haematol; 1985 Feb; 34(2):146-51. PubMed ID: 3856312
[TBL] [Abstract][Full Text] [Related]
24. Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
Mindner K; Ostermann G; Hochhaus A; Höche D; Till U
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):461-4. PubMed ID: 2465953
[TBL] [Abstract][Full Text] [Related]
25. [Levels of procollagen type III n-terminal peptide (PIIINP) in serum of patients with myeloproliferative syndrome (mps)].
Podolak-Dawidziak M; Wróbel T; Jeleń M
Pol Arch Med Wewn; 1998 Jan; 99(1):24-9. PubMed ID: 9686500
[TBL] [Abstract][Full Text] [Related]
26. Immunological localisation of beta-thromboglobulin and platelet factor 4 in human megakaryocytes and platelets.
McLaren KM; Pepper DS
J Clin Pathol; 1982 Nov; 35(11):1227-31. PubMed ID: 6183294
[TBL] [Abstract][Full Text] [Related]
27. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
29. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation.
Dalley A; Smith JM; Reilly JT; Neil SM
Br J Haematol; 1996 Jun; 93(4):856-62. PubMed ID: 8703817
[TBL] [Abstract][Full Text] [Related]
30. [Gray platelet syndrome, an example of myelofibrosis of megakaryocytic origin].
Caen JP; Cramer EM; Rendu F; Bryckaert M; Dupuy E; Levy-Toledano S
Bull Acad Natl Med; 1991 Oct; 175(7):1145-52; discussion 1152-3. PubMed ID: 1809489
[TBL] [Abstract][Full Text] [Related]
31. [Alteration of platelet function in myeloproliferative disorder and its clinical significance].
Ni HY; Deng CG; Ruan HF; Pam CF; Li HR; Gon DQ
Hua Xi Yi Ke Da Xue Xue Bao; 1988 Sep; 19(3):312-6. PubMed ID: 3253181
[No Abstract] [Full Text] [Related]
32. In vivo platelet release in myeloproliferative disorders.
Ireland H; Lane DA; Wolff S; Foadi M
Thromb Haemost; 1982 Aug; 48(1):41-5. PubMed ID: 6215739
[TBL] [Abstract][Full Text] [Related]
33. Plasma heparin neutralizing activity. Its use in the evaluation of thrombocytopenia and thrombocytosis.
Dana B; Carvalho AC; Ellman L
Am J Clin Pathol; 1976 Jun; 65(6):964-9. PubMed ID: 945687
[TBL] [Abstract][Full Text] [Related]
34. Does the beta TG/PF4 ratio have any value in myeloproliferative diseases?
Viero P; Cortelazzo S; Barbui T
Thromb Haemost; 1984 Jul; 51(3):411. PubMed ID: 6208631
[No Abstract] [Full Text] [Related]
35. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders.
Hibbin JA; Njoku OS; Matutes E; Lewis SM; Goldman JM
Br J Haematol; 1984 Jul; 57(3):495-503. PubMed ID: 6743569
[TBL] [Abstract][Full Text] [Related]
36. [Role of PDGF on myeloproliferative disorders].
Kimura A; Katoh O; Kuramoto A
Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
[No Abstract] [Full Text] [Related]
37. Immunohistological comparison of platelet factor 4 (PF4), fibronectin (Fn) and factor VIII related antigen (VIIIR:Ag) in human platelet granules.
Giddings JC; Brookes LR; Piovella F; Bloom AL
Br J Haematol; 1982 Sep; 52(1):79-88. PubMed ID: 6810914
[TBL] [Abstract][Full Text] [Related]
38. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
39. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Piletta GC
Am J Clin Pathol; 1991 Jan; 95(1):82-6. PubMed ID: 1987755
[TBL] [Abstract][Full Text] [Related]
40. Defective platelet aggregation and increased platelet turnover in patients with myelofibrosis and other myeloproliferative diseases.
Cunietti E; Gandini R; Mascaro G; Ferrari M; Pappalepore V; Scapellato L
Scand J Haematol; 1981 Apr; 26(4):339-44. PubMed ID: 6461058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
